Kidney Cancer UK
CheckMate data support 1st nivo–cabo in advanced RCC
CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma (RCC) report... Read More
#LWKC Webinar: Art Therapy & Mindfulness
We are very pleased to announce our FREE Art Therapy & Mindfulness #LWKCWebinar on Wednesday 1st December at 6.30pm. Explore your inner... Read More
NHS to trial blood test that can detect 50 types of cancer early
A blood test designed to detect more than 50 types of cancer, including kidney cancer, at an early stage will be trialled... Read More
Hepatitis C drug may be able to treat ccRCC
A drug inhibiting hepatitis C viral entry into cells may hold promise in treating clear cell renal cell carcinoma (ccRCC), as it... Read More
VHL Historic Treatment Breakthrough
FDA Approval of Breakthrough Treatment Brings Welcome Hope The US Food and Drug Administration (FDA) has approved the first-ever pharmaceutical treatment for... Read More
Cholesterol receptor emerges as novel therapeutic target in kidney cancer
Researchers at the Researchers at the Perelman School of Medicine at the University of Pennsylvania showed that inhibiting the HDL cholesterol receptor... Read More
Kidney cancer CT scan to piggy back mobile lung screening programmes
People taking part in a pioneering lung screening trial in Leeds will now also be checked for kidney cancer. A new study... Read More
Cabo+Nivo combo gets positive CHMP recommendation
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination With Opdivo® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma... Read More
First US patients dosed with novel imaging radiopharmaceutical for RCC
The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with... Read More
Watch Again – #LWKC Webinar: Let’s talk about Work
We are pleased to present the edited highlights of our #LWKC Webinar ”Let’s Talk About Work’, a conversation on working while living... Read More
Watch again – #LWKC Webinar: Treating Small Kidney Tumours
We are pleased to be able to present the edited highlights of our #LWKC Webinar ‘Treating Small Kidney Tumours – An overview... Read More
Cabo+Tecentriq combo shows promise in advanced ccRCC
Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma... Read More
SMC approves combination therapy for patients in Scotland
Kidney Cancer Scotland add their voice to those praising the Scottish Medicine Consortium’s (SMC) approval of the therapy Keytruda (pembrolizumab) in combination... Read More
NICE rejects pembro+axitinib therapy for aRCC
Kidney cancer community strongly disagrees with NICE decision not to approve pembrolizumab with axitinib therapy Kidney Cancer UK, the UK’s largest kidney... Read More
Serum reported to be a prognostic marker for RCC
There has been no clinically useful diagnostic or prognostic biomarker for renal cell carcinoma (RCC). Serum γ-glutamyltransferase (GGT) activity has been reported... Read More
Study shows Rise in Wilms Tumour
A study points to a rise in renal carcinomas in children, known as ‘Wilms Tumour’. Wilms tumour remains the most common type... Read More
RCC combo approved on CDF
The UK’s first as breakthrough kidney cancer combination treatment has been approved for immediate use through the Cancer Drugs Fund (CDF) in... Read More
Cabo/atezo phase 3 combo RCC trial launched
The phase 3 CONTACT-03 trial is exploring the combination of the multikinase inhibitor and immunotherapy agent in patients with renal cell carcinoma... Read More
Biomarker combo may help predict mRCC immuno response
When deciding on the best course of treatment for patients with metastatic renal cell carcinoma (mRCC), it’s difficult for oncologists to know... Read More
Leeds cancer nurse wins inaugural Melinda Whale Memorial Award 2019
A Leeds nurse was the first to receive a high-profile award recognising her dedication, care and unwavering support for kidney cancer patients.... Read More
Plans to ease guidance for over 2 million shielding
Advisory guidance to be eased for 2.2 million clinically extremely vulnerable people across England, as virus infection rates continue to fall From... Read More
Analysis findings from KEYNOTE-427 ccRCC trial
In an interview with Targeted Oncology, Scott Tykodi, MD, PhD, a physician with the Seattle Cancer Care Alliance, and associate professor in... Read More
Researchers underscore efficacy of Pembrolizumab+Axitinib in treating advanced Rcc
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma Researchers at Fox Chase Cancer Center, along... Read More
How GP’s should support ‘Shielded’ Patients
Patients who are most at risk of severe complications from COVID-19 have been asked to ‘shield’ themselves. This means that they should... Read More
